Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: Systematic review

Vaccine

Volumn 29, Issue 28, 2011, Pages 4544-4555

  Thomas, Roger E ^a   Lorenzetti, Diane L ^a   Spragins, Wendy ^b   Jackson, Dave ^b   Williamson, Tyler ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b Independent Research Consultants   (Canada)

^c Departments of Community Health Sciences and Family Medicine   (Canada)

Author keywords

Active surveillance; Risk of bias; Serious adverse effects; Systematic review; Yellow fever; Yellow fever 17D and 17DD vaccine

Indexed keywords

YELLOW FEVER VACCINE;

ANAPHYLACTIC SHOCK; AUSTRALIA; BRAZIL; DATA BASE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MENINGOENCEPHALITIS; NEUROLOGIC DISEASE; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SWITZERLAND; SYSTEMATIC REVIEW; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; URTICARIA; VACCINATION; YELLOW FEVER;

ADOLESCENT; ADULT; AUSTRALIA; BRAZIL; CHILD; CHILD, PRESCHOOL; FEMALE; GREAT BRITAIN; HUMANS; INFANT; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SWITZERLAND; VACCINATION; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS; YOUNG ADULT;

EID: 80955178331     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.055     Document Type: Review

References (87)

1. Barrett A.D., Monath T.P., Barban V., Niedrig M., Teuwen D.E. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine 2007, 25(15):2758-2765.
2. Meeting of Global Advisory Committee on Vaccine Safety, 18-19 June 2008. Wkly Epidemiol Rec 2008;83(32):287-92.
3. Bae H.-G., Domingo C., Tenorio A., de ory F., Muñoz J., Weber P., et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 2008, 197(11):1577-1584.
4. Guimard T., Minjolle S., Polard E., Fily F., Hervé H., Michelet C., et al. Incidence of yellow fever vaccine-associated neurotropic disease. Am J Trop Med Hyg 2009, 81(6):1141-1143.
5. Kelso J.M., Mootrey G.T., Tsai T.F. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 1999, 103(4):698-701.
6. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004, 22(17-18):2103-2105.
7. Levy S. Centers for Disease Control and Prevention (CDC). Adverse events associated with 17D-derived yellow fever vaccination - United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2002, 51(44):989-993.
8. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N., et al. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26(48):6077-6082.
9. McMahon A.W., Eidex R.W., Marfin A.A., Russell R., Sejvar J.J., Markoff L., et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007, 25(10):1727-1734.
10. Monath T., Cetron M., Teuwen D. Yellow fever vaccine. Vaccines 2008, 959-1056. Saunders/Elsevier, Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
11. Struchiner C.J., Luz P.M., Dourado I., Sato H.K., Aguiar S.G., Ribeiro J.G.L., et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect 2004, 132(5):939-946.
12. Vellozzi C., Mitchell T., Miller E., Casey C.G., Eidex R.B., Hayes E.B. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004. Am J Trop Med Hyg 2006, 75(2):333-336.
13. Whittembury A., Ramirez G., Hernández H., Ropero A.M., Watermen S., Ticona M., et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009, 27(43):5974-5981.
14. Bonhoeffer J., Kohl K., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002, 21(3-4):298-302.
15. Bonhoeffer J., Heininger U., Kohl K., Chen R.T., Duclos P., Heijbel H., et al. Standardized case definitions of adverse events following immunization (AEFI). Vaccine 2004, 22(5-6):547-550.
16. Gold M.S., Gidudu J., Erlewyn-Lajeunesse M., Law B. Can the Brighton Collaboration case definitions be used to improve the quality of adverse event following immunization (AEFI) reporting? Anaphylaxis as a case study. Vaccine 2010, 28(28):4487-4498.
17. Bonhoeffer J., Bentsi-Enchill A., Chen R.T., Fisher M.C., Gold M.S., Hartman K., et al. Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine 2009, 27(April 6 (16)):2289-2297.
18. Council for International Organizations of Medical Sciences (CIOMS). Reporting form for international reporting of adverse drug reactions. CIOMS 2011. Available from: URL: http://www.cioms.ch/.
19. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidelines for clinical safety assessment (E2a-e). ICH 2011. Available from: URL: http://www.ich.org/.
20. Belmusto-Worn V.E., Sanchez J.L., McCarthy K., Nichols R., Bautista C.T., Magill A.J., et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 2005, 72(2):189-197.
21. Oyelami S.A., Olaleye O.D., Oyejide C.O., Omilabu S.A., Fatunla B.A. Severe post-vaccination reaction to 17D yellow fever vaccine in Nigeria. Rev Roum Virol 1994, 45(1-2):25-30.
22. Nasidi A., Monath T.P., Vandenberg J., Tomori O., Calisher C.H., Hurtgen X., et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg 1993, 87(3):337-339.
23. WHO Emerging and Other Communicable Diseases. District guidelines for yellow fever surveillance. Geneva: World Health Organization; 1998. Report No.: WHO/EPI/GEN/98.09.
24. Ambrosch F., Friitzell B., Gregor J., Jonas S., Kollaritsch H., Teulieres L., et al. Combined vaccination against yellow fever and typhoid fever: a comparative trial. Vaccine 1994, 12(7):625-628.
25. Camacho L.A.B., Freire Mda S., Leal Mda L.F., de Aguiar S.G., do Nascimento J.P., Iguchi T., et al. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. Rev Saude Publica 2005, 39(3):413-420.
26. Cavalcanti D.P., Salomao M.A., Lopez-Camelo J., Pessoto M.A. Campinas group of yellow fever immunization during P. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health 2007, 12(7):833-837.
27. Dick G.W.A., Horgan E.S. Vaccination by scarification with a combined 17D yellow fever and vaccinia vaccine. J Hyg 1952, 50(3):376-383.
28. Dick G.W.A. A preliminary evaluation of the immunizing power of chick-embryo 17D yellow fever vaccine inoculated by scarification. Am J Hyg 1952, 55:140-153.
29. Edwan T. Yellow fever vaccination for the Jordanian peace keeping forces. Jordan Med J 2004, 38(1):84-87. 109.
30. Fitzner J., Coulibaly D., Kouadio D.E., Yavo J.C., Loukou Y.G., Koudou P.O., et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. Vaccine 2004, 23(2):156-162.
31. Hahn R.G. A combined yellow fever-smallpox vaccine for cutaneous application. Am J Hyg 1951, 54:50-70.
32. Lang J., Zuckerman J.N., Clarke P., Barrett P., Kirkpatrick C., Blondeau C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med 1999, 60(6):1045-1050.
33. Lhuillier M., Mazzariol M.J., Zadi S., Le Cam N., Bentejac M.C., Adamowicz L., et al. Study of combined vaccination against yellow fever and measles in infants from six to nine months. J Biol Stand 1989, 17(January (1)):9-15.
34. Monath T.P., Nichols R., Archambault W.T., Moore L., Marchesani R., Tian J., et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002, 66(5):533-541.
35. Monath T.P., Cetron M.S., McCarthy K., Nichols R., Archambault W.T., Weld L., et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 2005, 1(5):207-214.
36. Moss-Blundell A.J., Bernstein S., Shepherd W.M., Langford D.T., Ferris R., Kelly A. A clinical study of stabilized 17D strain live attenuated yellow fever vaccine. J Biol Stand 1981, 9(4):445-452.
37. Osei-Kwasi M., Dunyo S.K., Koram K.A., Afari E.A., Odoom J.K., Nkrumah F.K. Antibody response to 17D yellow fever vaccine in Ghanaian infants. Bull World Health Organ 2001, 79(11):1056-1059.
38. Panthier R., Husson R.A. Yellow fever vaccination (17-D) and allergy. Bull Soc Pathol Exot Filiales 1957, 50(1):23-28.
39. Papaiordanou P., Sato H., Freire M., Yamamura A., Gouveia F., Amaral E. Yellow fever vaccination during pregnancy. Abstracts of the interscience conference on antimicrobial agents and chemotherapy 2001, 41.
40. Pfister M., Kürsteiner O., Hilfiker H., Favre D., Durrer P., Ennaji A., et al. Immunogenecity and safety of Berna-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med 2005, 72(3):339-346.
41. Pivetaud J.P., Raccurt C.P., M'Bailara L., Le Vigouroux A., Le Bras M. Reactions to vaccination against yellow fever. Bull Soc Pathol Exot Filiales 1986, 79(5 Pt 2):772-776.
42. Roche J.C., Jouan A., Brisou B., Rodhain R., Fritzell B., Hannoun C. Comparative clinical study of a new 17D thermostable yellow fever vaccine. Vaccine 1986, 4(3):163-165.
43. Smith H.H., Penna H.A., Paoliello A. Yellow fever vaccination with cultured virus (17D) without immune serum. Am J Trop Med 1938, s1-18(5):437-468.
44. Soula G., Sylla A., Pichard E., Kodio B., Bentejac A.C., Teulières L., et al. A new combined vaccine against yellow fever and measles in infants aged 6 to 24 months in Mali. Bull Soc Pathol Exot 1991, 84(5 Pt. 5):885-897.
45. Suzano C.E., Amaral E., Sato H.K., Papaiordanou P.M. Campinas group on yellow fever immunization during P. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 2006, 24(9):1421-1426.
46. Tauraso N.M., Myers M.G., Nau E.V., O'Brien T.C., Spindel S.S., Trimmer R.W. Effect of interval between inoculation of live smallpox and yellow-fever vaccines on antigenicity in man. J Infect Dis 1972, 126(4):362-371.
47. Veit O., Niedrig M., Chapuis-Taillard C., Cavassini M., Mossdorf E., Schmid P., et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 2009, 48(5):659-666.
48. Smith H.H., Penna.F HA, Paoliello A. Yellow fever vaccination with cultured virus (17D) without immune serum. Am J Trop Med 1938, s1-18(5):437-468.
49. Veit O., Hatz C., Niedrig M., Furrer H. Yellow fever vaccination in HIV-infected patients. HIV Therapy 2010, 4(1):17-26.
50. Review of adverse events reported following use of yellow fever vaccine - Canada, 1987-2000. Can Commun Dis Rep 2002;28(2):9-15.
51. From the Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination - United States, 2001-2002. JAMA 2002;288(20):2533-5.
52. Bentancourt S., Valsecia M., Perez A., Bergman M., Bignone K. Adverse events supposedly attributable to vaccination of yellow fever. Drug Safety 2008, 31(10):942.
53. Fernandes G.C., Camacho L.A., Sa Carvalho M. Surveillance system of vaccine adverse events and local data analysis - the experience in a middle-sized city in Brazil, 1999-2001. Vaccine 2005, 23(17-18):2349-2353.
54. Fernandes G.C., Camacho L.A., Sa Carvalho M., Batista M., de Almeida S.M. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005. Vaccine 2007, 25(16):3124-3128.
55. Khromava A.Y., Eidex R.B., Weld L.H., Hohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23(25):3256-3263.
56. Lawrence G., Menzies R., Burgess M., McIntyre P., Wood N., Boyd N., et al. Surveillance of adverse events following immunisation: Australia, 2000-2002. Commun Dis Intell 2003, 27(3):307-323.
57. Lawrence G.L., Burgess M.A., Kass R.B. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell 2004, 28(2):244-248.
58. Martin M., Weld L.H., Tsai T.F., Mootrey G.T., Chen R.T., Niu M., et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001, 7(6):945-951.
59. Martins RdeM, Maia MdeLdeS, dos Santos EM, Cruz RLdeS, dos Santos PRG, Carvalho SMD, et al. Yellow fever vaccine post-marketing surveillance in Brazil. Procedia Vaccinol 2010;2(2):178-83.
60. Schumacher Z., Bourquin C., Heininger U. Surveillance for adverse events following immunization (AEFI) in Switzerland-1991-2001. Vaccine 2010, 28(24):4059-4064.
61. Souayah N., Nasar A., Suri M.F.K., Qureshi A.I. Guillain-Barre syndrome after vaccination in United States. A report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine 2007, 25(29):5253-5255.
62. Diop Mar I., Niang I., Guicheney A., Berne C., Collomb H., Rey M., et al. Encephalitis following anti-yellow fever vaccination (from 248 cases observed at Dakar in 1965). Ann Pediatr (Paris) 1967, 14(3):181-191.
63. Diop Mar I., Ayats H., Rey M. The problem of post-yellow fever vaccination encephalitis. Bull Soc Med Afrique Noire Langue Francaise 1970, 15(3):468-479.
64. Vasconcelos P.F.C., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L.R.S., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001, 358(9276):91-97.
65. World Health Organization. Prevention and control of yellow fever in Africa. Geneva: World Health Organization; 1986.
66. Da Mota L.M.H., Oliveira A.C.V., Lima R.A.C., Dos Santos-Neto L.L., Tauil P.L. Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases. Rev Soc Bras Med Trop 2009, 42(1):23-27.
67. Kouwenaar W. The reaction to yellow fever vaccine (17D), particularly in allergic individuals. Doc Med Geogr Trop 1953, 5(1):75-84.
68. Pritchard J., Mukherjee R., Hughes R.A.C. Risk of relapse of Guillain-Barre syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation. J Neurol Neurosurg Psychiatry 2002, 73(3):348-349.
69. Roodyn L. Encephalitis after yellow fever vaccination. Br Med J 1954, 2(4898):1226.
70. Wolga J., Rodhain F., Hannoun C., Dodin A., Fritzell B., Loucq C., et al. Evaluation of thermostable yellow fever vaccine from the Pasteur Institute on international travellers. J Biol Stand 1986, 14(4):289-295.
71. Haas L. Encephalitis after yellow-fever vaccination. Br Med J 1954, 2(4894):992-993.
72. Scott L.G. Encephalitis after yellow-fever vaccination. Br Med J 1954, 2(4896):1108.
73. Smith J.H. Encephalitis in an infant after vaccination with 17 D yellow fever virus. Br Med J 1954, 2(4892):852.
74. Cannon D. Encephalitis after yellow fever vaccination. Br Med J 1955, 1(4921):1090.
75. Mouchon D., Pignon D., Vicens R., Thanh T.-H., Tekaia F., Teulières L., et al. The combined measles-yellow fever vaccination in African infants aged 6 to 10 months. Bull Soc Pathol Exot 1990, 83(4):537-551.
76. Anonymous. Global advisory committee on vaccine safety, 16-17 June 2010. Wkly Epidemiol Rec 2010;85(30):285-91.
77. D'Acremont V., Tremblay S., Genton B. Impact of vaccines given during pregnancy on the offspring of women consulting a travel clinic: a longitudinal study. J Travel Med 2008, 15(2):77-81.
78. Nishioka Sde A., Nunes-Araujo F.R., Pires W.P., Silva F.A., Costa H.L. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop Med Int Health 1998, 3(1):29-33.
79. Robert E., Vial T., Schaefer C., Arnon J., Reuvers M. Exposure to yellow fever vaccine in early pregnancy. Vaccine 1999, 17(3):283-285.
80. Tsai T.F., Paul R., Lynberg M.C., Letson G.W. Congenital yellow fever virus infection after immunization in pregnancy. J Infect Dis 1993, 168(6):1520-1523.
81. Goujon C., Tohr M., Feuillie V., Coulaud P., Dupont B., Sansonetti P. Good tolerance and efficacy of yellow fever vaccine among carriers of human immunodeficiency virus. J Travel Med 1995, 2(2):145.
82. Ho Y.L., Enohata T., Lopes M.H., De Sousa Dos S.S. Vaccination in Brazilian HIV-infected adults: a cross-sectional study. AIDS Patient Care STDS 2008, 22(1):65-70.
83. Pacanowski J, Campa P, Dabrowska M, Lacombe K. Antibody response and safety of yellow fever vaccination in HIV infected patients. 48th Annual ICAAC (Washington, DC, October 25-28, 2008) 2008; Poster No. G 392.
84. Pistone T., Verdiere C.H., Receveur M.C., Ezzedine K., Lafon M.E., Malvy D. Immunogenicity and safety of yellow fever vaccine in HIV-living travelers, France, 2005. (Special Issue: Travelers' health 2007.). Bull Epidemiol Hebd 2007, 25/26:238-240.
85. Receveur M.C., Thiebaut R., Vedy S., Malvy D., Mercie P., Bras M.L. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin Infect Dis 2000, 31(3):E7-E8.
86. Tattevin P., Depatureaux A.G., Chapplain T.M., Dupont M., Souala F., Arvieux C., et al. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS 2004, 18(5):825-827.
87. Pistone T., Verdiere C.H., Receveur M.C., Ezzedine K., Lafon M.E., Malvy D. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients. Curr HIV Res 2010, 8(September (6)):461-466.